--
International Journal of Scientific Development and Research - IJSDR
(An International Open Access Journal)
ISSN:
2455-2631


Issue: November 2021

Volume 6 | Issue 11

Impact factor: 5.47

Click Here For more Info

Imp Links for Author
Imp Links for Reviewer
Research Area
Subscribe IJSDR
Visitor Counter

Copyright Infringement Claims
Indexing Partner
Published Paper Details
Paper Title: Human CDC2-Like Kinase 1 (CLK1): A Novel Target for Alzheimer’s Disease
Authors Name: Ravindra Mishra , Piyush Pankaj , Darakhshan Gazala Bari , Dr.Saurabh Sharma
Unique Id: IJSDR1912046
Published In: Volume 4 Issue 12, December-2019
Abstract: The cdc2-like kinases (CLKs) are an evolutionarily conserved group of dual specificity kinases belonging to the CMGC (cyclin-dependent kinases (CDKs), mitogen-activated protein kinases (MAP kinases), glycogen synthase kinases (GSK) and CDK-like kinases). The CLK family consists of four isoforms namely CLK1, CLK2, CLK3 and CLK4. The human CLK1 encoded protein comprises 454 amino acids and the catalytic domain of CLK1 exhibits the typi- cal protein kinase fold. CLK1 has been shown to autophosphorylate on serine, threonine and tyrosine residues and phos- phorylate exogenous substrates on serine and threonine residues. CLK1 plays an important role in the regulation of RNA splicing through phosphorylation of members of the serine and arginine-rich (SR) family of splicing factors. CLK1 is in- volved in the pathophysiology of Alzheimer’s disease by phosphorylating the serine residue in SR proteins. Nuclear speckles of the nucleoplasm contain the stored form of SR proteins and are moderately responsible for the choice of splic- ing sites during pre-mRNA splicing. Hence, the inhibition of CLK1 can be used as a therapeutic strategy for Alzheimer’s disease. Many natural and synthetic molecules are reported to possess CLK1 inhibitory activity. Some specific examples are Marine alkaloid Leucettamine B and KH-CB19. Leucettamine B is a potent inhibitor of CLK1 (15 nM), Dyrk1A (40 nM), and Dyrk2 (35 nM) and a moderate inhibitor of CLK3 (4.5 µM) whereas KH-CB19 is a highly specific and potent inhibitor of the CLK1/CLK4. X-ray crystallographic studies have revealed that the marine sponge metabolite hymeniald- isine and a dichloroindolyl enamino nitrile (KH-CB19) have binding interaction to CLK1. This review focuses on the role of CLKs in the pathophysiology of Alzheimer's disease and therapeutic potential of targeting CLK1 in Alzheimer's dis- ease drug discovery and development. In addition, the recent developments in drug discovery efforts targeting human CDC2-like kinase 1 are also highlighted.
Keywords: Cdc2 like kinase (CLK), Alzheimer, SR proteins, protein kinases, CLK1 inhibitors.
Cite Article: "Human CDC2-Like Kinase 1 (CLK1): A Novel Target for Alzheimer’s Disease", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.4, Issue 12, page no.232 - 240, December-2019, Available :http://www.ijsdr.org/papers/IJSDR1912046.pdf
Downloads: 00060116
Publication Details: Published Paper ID: IJSDR1912046
Registration ID:191993
Published In: Volume 4 Issue 12, December-2019
DOI (Digital Object Identifier):
Page No: 232 - 240
Publisher: IJSDR | www.ijsdr.org
ISSN Number: 2455-2631

Click Here to Download This Article

Article Preview

Click here for Article Preview







Major Indexing from www.ijsdr.org
Google Scholar ResearcherID Thomson Reuters Mendeley : reference manager Academia.edu
arXiv.org : cornell university library Research Gate CiteSeerX DOAJ : Directory of Open Access Journals
DRJI Index Copernicus International Scribd DocStoc

Track Paper
Important Links
Conference Proposal
ISSN
DOI (A digital object identifier)


Providing A digital object identifier by DOI
How to GET DOI and Hard Copy Related
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Creative Commons License
This material is Open Knowledge
This material is Open Data
This material is Open Content
Social Media
IJSDR